Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Asset Writedowns and Impairment (2023 - 2024)

Kezar Life Sciences' Asset Writedowns and Impairment history spans 2 years, with the latest figure at -$1.5 million for Q4 2024.

  • For Q4 2024, Asset Writedowns and Impairment fell 157.37% year-over-year to -$1.5 million; the TTM value through Sep 2025 reached -$49000.0, down 101.17%, while the annual FY2023 figure was $2.7 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q4 2024 was -$1.5 million at Kezar Life Sciences, down from $1.5 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2.7 million in Q4 2023 and bottomed at -$1.5 million in Q4 2024.